WINT vs. GMDAQ, ELOX, ALBT, FNCH, SCNI, KRBP, SQZ, TCBP, TCON, and FRTX
Should you be buying Windtree Therapeutics stock or one of its competitors? The main competitors of Windtree Therapeutics include Gamida Cell (GMDAQ), Eloxx Pharmaceuticals (ELOX), Avalon GloboCare (ALBT), Finch Therapeutics Group (FNCH), Scinai Immunotherapeutics (SCNI), Kiromic BioPharma (KRBP), SQZ Biotechnologies (SQZ), TC Biopharm (TCBP), TRACON Pharmaceuticals (TCON), and Fresh Tracks Therapeutics (FRTX). These companies are all part of the "biological products, except diagnostic" industry.
Windtree Therapeutics (NASDAQ:WINT) and Gamida Cell (NASDAQ:GMDAQ) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends, community ranking and institutional ownership.
Windtree Therapeutics has higher earnings, but lower revenue than Gamida Cell. Gamida Cell is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.
Windtree Therapeutics has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500. Comparatively, Gamida Cell has a beta of 1.14, indicating that its share price is 14% more volatile than the S&P 500.
Windtree Therapeutics received 3 more outperform votes than Gamida Cell when rated by MarketBeat users.
29.3% of Windtree Therapeutics shares are held by institutional investors. Comparatively, 50.3% of Gamida Cell shares are held by institutional investors. 0.5% of Windtree Therapeutics shares are held by company insiders. Comparatively, 6.7% of Gamida Cell shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Gamida Cell's return on equity of 0.00% beat Windtree Therapeutics' return on equity.
In the previous week, Gamida Cell had 1 more articles in the media than Windtree Therapeutics. MarketBeat recorded 1 mentions for Gamida Cell and 0 mentions for Windtree Therapeutics. Windtree Therapeutics' average media sentiment score of 0.00 equaled Gamida Cell'saverage media sentiment score.
Summary
Gamida Cell beats Windtree Therapeutics on 7 of the 11 factors compared between the two stocks.
Get Windtree Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for WINT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding WINT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Windtree Therapeutics Competitors List
Related Companies and Tools
